Adam Feuerstein

Latest stories

4d
TheStreet.com
Biotech Stocks Recover From Early-Morning Flash CrashNEW YORK (TheStreet) -- It could be worse. A lot worse. The iShares Nasdaq Bio
Biotech Stocks Recover From Early-Morning Flash Crash
TheStreet.com / Posted 4 days ago
NEW YORK (TheStreet) -- It could be worse. A lot worse. The iShares Nasdaq Biotechnology Index (IBB), the most closely followed biotech sector index, is down less than 1% to 339.61. That's an almost miraculous recovery considering the IBB plunged... Read more
9d
TheStreet.com
Biotech Stocks Get Burned This Summer, but Fall Might Bring ReliefBOSTON (TheStreet) -- I'm back at work after a nice, 10-day vacation. I had gre
Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief
TheStreet.com / Posted 9 days ago
BOSTON (TheStreet) -- I'm back at work after a nice, 10-day vacation. I had great time away from biotech stocks, thanks for asking. It doesn't look like I missed much in the news department, but valuations of biotech stocks are nearing a 10% decline... Read more
17d
MedCity News
Checkmate nets $20M for checkpoint inhibitor helpersThe name of the company’s pretty pithy: Checkmate Pharmaceuticals, so-called be
Checkmate nets $20M for checkpoint inhibitor helpers
MedCity News / Posted 17 days ago
The name of the company’s pretty pithy: Checkmate Pharmaceuticals, so-called because its drug in development serves as a “mate” to checkpoint inhibitors, enhancing their efficacy. The Cambridge company just launched with a $20 million Series A –... Read more
24d
TheStreet.com
Seven Reasons to Love Biomarin's Duchenne Drug Falls One ShortYee's reason No. 2 means little. Reason Nos. 3, 4 and 6 generally work in BioMa
Seven Reasons to Love Biomarin's Duchenne Drug Falls One Short
TheStreet.com / Posted 24 days ago
Yee's reason No. 2 means little. Reason Nos. 3, 4 and 6 generally work in BioMarin's favor, agreed, but that doesn't alleviate all the risk. A safety database of 300-plus patients on drisapersen is far more than what rival Sarepta Therapeutics(SRPT -... Read more
29d
TheStreet.com
MannKind Afrezza Sales Underwhelming Again, Sanofi ReportsWhether you prefer sales reported in euros or converted into dollars ($2.2 mill
MannKind Afrezza Sales Underwhelming Again, Sanofi Reports
TheStreet.com / Posted 29 days ago
Whether you prefer sales reported in euros or converted into dollars ($2.2 million), Afrezza's performance in the first full quarter of its commercial launch was poor. The only saving grace is that no one, not even the most Kool Aid-drinking MannKind... Read more
1m
TheStreet.com
Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good)FOSTER CITY, Calif. (TheStreet) -- Gilead Sciences(GILD - Get Report) will not
Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good)
TheStreet.com / Posted a month ago
FOSTER CITY, Calif. (TheStreet) -- Gilead Sciences(GILD - Get Report) will not be blamed for a cooling of the biotech bull market, if any such thing exists. Second-quarter earnings and revenue topped Street expectations, bolstered by really strong... Read more
7 related stories
1m
TheStreet.com
Struggling Sanofi (SNY) Sends Cancer SOS to Regeneron and Another Vanity Biotech (NK) IPO LaunchesNEW YORK (TheStreet) -- It's a day that ends in "day," which means cancer immun
Struggling Sanofi (SNY) Sends Cancer SOS to Regeneron and Another Vanity Biotech (NK) IPO Launches
TheStreet.com / Posted a month ago
NEW YORK (TheStreet) -- It's a day that ends in "day," which means cancer immunotherapy is dominating the biotech news. Len is Leonard Schleifer, CEO of Regeneron Pharmaceuticals , the large-cap biotech company which also serves as struggling... Read more
m
TheStreet.com
Gilead (GILD) Can Soothe Biotech Investor Fears with Great 2Q EarningsPlease report boffo second-quarter earnings and raise guidance for the rest of
Gilead (GILD) Can Soothe Biotech Investor Fears with Great 2Q Earnings
TheStreet.com / Posted 1 months ago
Please report boffo second-quarter earnings and raise guidance for the rest of the year. Love and kisses -- Anxious Biotech Investors. It's probably hyperbolic to say the fate of the entire biotech sector wrests on the shoulders of Gilead, but the... Read more
7 related stories
m
TheStreet.com
Biogen's Possible Takeout Targets and Other Key Questions After Blow1. Will Biogen buy itself back into investors' good graces? Isis Pharmaceutica
Biogen's Possible Takeout Targets and Other Key Questions After Blow
TheStreet.com / Posted 1 months ago
1. Will Biogen buy itself back into investors' good graces? Isis Pharmaceuticals (ISIS) might be the most obvious Biogen takeout target given its existing partnership, but is it the smart move? Biogen is getting dinged lately, in part because... Read more

People in this news